abrdn Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

abrdn Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$19.6M	Buy	151,725 +10,356	+7%	+$1.25M	0.07%	150
2017 Q1	$15.5M	Sell	141,369 -145,857	-51%	-$12.8M	0.05%	150
2016 Q4	$21.2M	Sell	287,226 -268,427	-48%	-$21.8M	0.07%	140
2016 Q3	$48.5M	Sell	555,653 -12,704	-2%	-$1.2M	0.2%	113
2016 Q2	$48.9M	Sell	568,357 -209,271	-27%	-$18.1M	0.22%	98
2016 Q1	$61.8M	Sell	777,628 -5,347	-0.7%	-$484K	0.28%	91
2015 Q4	$98.5M	Buy	+782,975	New	+$94.5M	0.42%	75
2015 Q1	–	Sell	-4,171	Closed	-$496K	–	421
2014 Q4	$496K	Sell	4,171 -5,782	-58%	-$651K	﹤0.01%	339
2014 Q3	$1.12M	Sell	9,953 -583,386	-98%	-$55.5M	﹤0.01%	280
2014 Q2	$56.2M	Buy	593,339 +24,727	+4%	+$1.73M	0.25%	108
2014 Q1	$40.2M	Buy	568,612 +486,236	+590%	+$38.5M	0.19%	112
2013 Q4	$6.12M	Sell	82,376 -8,936	-10%	-$622K	0.03%	175
2013 Q3	$6.92M	Buy	91,312 +11,806	+15%	+$939K	0.04%	151
2013 Q2	$6.36M	Buy	+79,506	New	+$5.86M	0.04%	153

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

abrdn Investment Management's VRTX Position: Q2 2017 in Review

abrdn Investment Management increased its Vertex Pharmaceuticals (VRTX) stake by 7.3% in Q2 2017, buying an estimated $1.25M and bringing the position to 151,725 shares worth $19.6M. The position accounts for 0.07% of the portfolio, ranked #150.

abrdn Investment Management first reported a position in VRTX in Q2 2013 and has held it in 14 quarters since. The position peaked at $98.5M in Q4 2015. 582 funds tracked by Wall St. Rank hold VRTX as of Q2 2017.

abrdn Investment Management held 151,725 shares of Vertex Pharmaceuticals worth $19.6M as of Q2 2017.
abrdn Investment Management bought 10,356 Vertex Pharmaceuticals shares in Q2 2017, an estimated $1.25M.
Vertex Pharmaceuticals made up 0.07% of abrdn Investment Management's portfolio in Q2 2017, its #150 holding.
abrdn Investment Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 14 quarters since.
abrdn Investment Management's Vertex Pharmaceuticals position peaked at $98.5M in Q4 2015.
582 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2017.

Based on abrdn Investment Management's 13F filing for Q2 2017, filed 10 Aug 2017.